Literature DB >> 10175982

How to calculate indirect costs in economic evaluations.

B Liljas1.   

Abstract

This article describes the components that should be included as indirect costs to be consistent with economic theory in studies conducted from a societal perspective. The recently proposed method of how to estimate indirect costs, the friction-cost approach, is shown to exclude many aspects of these indirect cost components. Furthermore, it is demonstrated that this approach rests on very strong assumptions about the individual's valuation of leisure and about the labour market. This approach does not, in most realistic circumstances, have a foundation in economic theory. It also shows that all indirect costs cannot be assumed to be included in the individual's reported utility weight for a health state [used to determine quality-adjusted life-year (QALY) values], as recently suggested by the US Panel for Cost-Effectiveness Analysis of Health and Medicine. Therefore, to be consistent with economic theory, neither the friction-cost approach nor the QALY approach can be recommended over the more commonly used human capital-cost approach for estimating the indirect costs of a disease in economic evaluations from a societal perspective.

Entities:  

Mesh:

Year:  1998        PMID: 10175982     DOI: 10.2165/00019053-199813010-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  76 in total

1.  Pharmacoeconomics and health policy. Current applications and prospects for the future.

Authors:  P E Greenberg; A Arcelus; H G Birnbaum; P Y Cremieux; J LeLorier; P Ouellette; M B Slavin
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

Review 2.  Recent advances in the methods of cost-benefit analysis in healthcare. Matching the art to the science.

Authors:  E McIntosh; C Donaldson; M Ryan
Journal:  Pharmacoeconomics       Date:  1999-04       Impact factor: 4.981

3.  How to calculate indirect costs in economic evaluations.

Authors:  W B Brouwer; M A Koopmanschap
Journal:  Pharmacoeconomics       Date:  1998-05       Impact factor: 4.981

4.  The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.

Authors:  R C Dodel; M Singer; R Köhne-Volland; T Szucs; B Rathay; E Scholz; W H Oertel
Journal:  Pharmacoeconomics       Date:  1998-09       Impact factor: 4.981

Review 5.  The economic cost of epilepsy: a review.

Authors:  M Brunetti; E Pagano; L Garattini
Journal:  Ital J Neurol Sci       Date:  1998-04

Review 6.  A review of health-related workplace productivity loss instruments.

Authors:  Jennifer H Lofland; Laura Pizzi; Kevin D Frick
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

7.  Economic benefits of achieving realistic smoking cessation targets in Australia.

Authors:  Anne Magnus; Dominique Cadilhac; Lauren Sheppard; Toby Cumming; Dora Pearce; Rob Carter
Journal:  Am J Public Health       Date:  2010-12-16       Impact factor: 9.308

8.  Crisis, suicide and labour productivity losses in Spain.

Authors:  Berta Rivera; Bruno Casal; Luis Currais
Journal:  Eur J Health Econ       Date:  2016-01-22

Review 9.  The humanistic and economic burden of systemic lupus erythematosus : a systematic review.

Authors:  Rachel Meacock; Nicola Dale; Mark J Harrison
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

10.  Indirect costs in ambulatory patients with HIV/AIDS in Spain: a pilot study.

Authors:  Juan Oliva; César Roa; Juan del Llano
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.